Testing an antibody treatment for high-risk COVID-19 patients
Part of Infections, Lungs & breathing clinical trials.
This study tests a new antibody medicine for people with COVID-19 who are at high risk of getting very sick. If you qualify, you would receive the study drug or a placebo (inactive substance) to see if it helps you recover without needing to go to the hospital.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older (or a legal guardian can sign for you).
- You have tested positive for COVID-19 within the last 3 days.
- Your symptoms started 7 days ago or less.
- You are not currently in the hospital.
- You have at least two COVID-19 symptoms and one risk factor (like heart disease, diabetes, or older age).
- You have not had COVID-19 before, and you haven't had a COVID-19 vaccine or convalescent plasma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug (called B10-FC) to see if it's safe and how the body processes it. It is given once to healthy adults, and later to people with mild or moderate COVID-19 who are at higher risk of getting very sick.
This trial tests a new antiviral pill, secutrelvir, for people with mild to moderate covid-19 who are at higher risk of getting seriously ill. It aims to see if the drug can prevent hospitalization or severe disease.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
This trial tests whether donated “recovered patient” plasma (antibodies from people who had COVID-19) can improve outcomes for people hospitalized with COVID-19. It focuses on patients early in their illness who need a small amount of oxygen.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.